The International Journal of Cancer Management is a distinguished publication dedicated to advancing knowledge and research in the fields of cancer management, oncology, pharmacology, and radiology. Published by BRIEFLAND in the Netherlands, this journal serves as a vital resource for researchers, healthcare professionals, and students interested in the latest developments in cancer care and treatment strategies. With an ISSN of 2538-4422 and an E-ISSN of 2538-497X, the journal features a range of peer-reviewed articles that cover diverse aspects of cancer management, reflecting its commitment to high-quality, impactful research. The journal ranks in the Q4 category for Cancer Research and Oncology and Q3 for both Pharmacology and Surgery in 2023, signifying its growing influence in the scientific community. Through its open access format, the International Journal of Cancer Management ensures that critical research findings are accessible to all, promoting collaboration and innovation in the battle against cancer. Researchers looking to share their findings or learn more about current trends will find this journal an invaluable addition to their professional toolkit.

Rehabilitation Oncology, published by Lippincott Williams & Wilkins, is an essential academic journal dedicated to the interdisciplinary field of cancer rehabilitation. Since its inception in 2008, it has provided a platform for illuminating research, clinical practices, and innovative therapies aimed at improving the quality of life for cancer survivors. With an ISSN of 2168-3808 and an E-ISSN of 2381-2427, the journal covers a wide spectrum of topics, making significant contributions across various categories including Oncology, Rehabilitation, and Physical Therapy. Although currently not Open Access, the journal has garnered a notable 2023 Impact Factor status, placing it in the Q3 quadrant across multiple relevant disciplines as per the latest Scopus rankings. This reflects its growing influence in the rehabilitation community and offers vital insights for practitioners and researchers seeking to advance their understanding of patient care post-cancer treatment. With its focus on bridging the gap between research and real-world application, Rehabilitation Oncology serves as a vital resource for healthcare professionals committed to enhancing recovery outcomes in their patients.

Seminars in Oncology Nursing, published by Elsevier Science Inc, serves as a cornerstone for the field of oncology nursing, facilitating the dissemination of high-quality research and clinical practice insights since 1985. This quarterly journal, with significant impact as reflected in its Q2 ranking in the Nursing category for Oncology, provides an essential platform for the authors to share their findings, experiences, and innovations that can enhance patient care in oncology settings. With its ISSN 0749-2081 and E-ISSN 1878-3449, the journal offers a comprehensive access to a wealth of articles that emphasize evidence-based practices, care models, and the evolving challenges faced by oncology nurses. Targeted towards researchers, clinicians, and students, Seminars in Oncology Nursing not only contributes to academic discourse but also supports the professional development of its readership, ultimately advancing the field of oncology nursing.

CANCER, published by Wiley, stands as a pivotal journal in the field of oncology and cancer research, boasting an impressive impact factor and consistently dynamic growth since its inception in 1948. With an ISSN of 0008-543X and an E-ISSN of 1097-0142, this esteemed journal is recognized for its rigorous peer-reviewed articles, making significant contributions to the understanding of cancer biology, treatment modalities, and clinical practices. CANCER holds a distinguished position in the academic community, securing its placement in the Q1 category for both cancer research and oncology, and ranks within the top percentiles on Scopus, indicating its high impact and relevance. The journal is particularly beneficial for researchers, professionals, and students seeking to stay abreast of the latest advancements in cancer science. By addressing essential research questions and providing pathways for new therapies, CANCER continues to play a crucial role in shaping the future of oncology and improving patient outcomes.

Breast Cancer is a prestigious peer-reviewed journal published by SPRINGER JAPAN KK, specializing in the multifaceted domains of oncology and medical pharmacology. With an impressive impact factor and recognized within the Q1 category in multiple areas, including Medicine (miscellaneous), Radiology, and Nuclear Medicine and Imaging, this journal serves as a fundamental resource for cutting-edge research and clinical advancements in breast cancer treatment and care. Its indexed presence in renowned databases like Scopus further affirms its significance, ranking 56th in Radiology and 60th in Pharmacology. The journal aims to bridge the gap between clinical practice and scientific research by publishing original articles, reviews, and case studies that enhance understanding and improve patient outcomes. With converged content available from 1994 to 2024, the journal is dedicated to fostering innovative research while engaging a global audience of researchers, clinicians, and students passionate about tackling breast cancer challenges.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, published by Springer, is a prestigious peer-reviewed journal dedicated to advancing the fields of cancer research and clinical oncology. With an impact factor reflecting its significance within the academic community, the journal operates under a rigorous quality standard and offers a wealth of knowledge spanning from 1979 and continuing through 2025. With its comprehensive scope, it encompasses a wide array of topics including novel therapeutic strategies, clinical trials, and cutting-edge research methodologies, making it an essential resource for researchers, practitioners, and students alike. The journal’s category quartiles highlight its competitive edge, ranking Q2 in Cancer Research and Q1 in Medicine (miscellaneous) as of 2023. This positioning underscores its role at the forefront of oncology discourse. Through this journal, contributors and readers alike engage with impactful research that informs clinical practices and enhances patient care in oncology. Access to the journal’s content, although not open access, ensures curated and high-quality insights available to the academic and professional community.

Cancer Control is a prominent open-access journal published by SAGE Publications Inc, dedicated to advancing the field of oncology, hematology, and general medicine since its inception in 1995. With a focus on disseminating high-quality research, the journal contributes significantly to the knowledge base surrounding cancer prevention, treatment, and survivorship, making it a vital resource for researchers, healthcare professionals, and students alike. The journal currently holds a commendable position in the academic landscape, ranking in the Q2 category for both Hematology and Oncology, highlighting its impact and scholarly relevance. Available in an open-access format since 2018, Cancer Control ensures that critical findings are accessible to a broad audience, promoting collaboration and innovation in cancer-related research. Whether you're interested in the latest clinical trials, epidemiological studies, or public health initiatives, this journal serves as a key platform for sharing significant developments in cancer care and control.

Journal of Diabetes Investigation is a prestigious open-access journal published by WILEY, dedicated to advancing knowledge in the fields of Endocrinology, Diabetes, and Metabolism. With its ISSN 2040-1116 and E-ISSN 2040-1124, the journal provides a vital platform for researchers, healthcare professionals, and students to disseminate high-quality research, foster innovative ideas, and engage with cutting-edge developments in diabetes investigation. Since its inception in 2010, the journal has established a solid reputation, ranking in Q2 for Endocrinology and Diabetes and Metabolism, and Q1 for both Internal Medicine and Miscellaneous Medicine categories in 2023. Its Scopus rankings further underscore its impact, notably at the 76th percentile in Internal Medicine. The open access model, adopted in 2014, ensures that vital information is freely available, promoting global collaboration and knowledge sharing. The journal is not only a reflection of Australia's commitment to medical research but also a beacon for advancements that can ultimately enhance patient outcomes in diabetes care.

The Disability and Health Journal, published by Elsevier Science Inc, is a leading peer-reviewed platform that focuses on the interconnections between disability and health management. With its impact factor underscoring its significance at Q1 in both Medicine and Public Health, Environmental and Occupational Health, this journal stands out for its comprehensive analysis and dissemination of research covering the range of public health issues affecting individuals with disabilities. Spanning research from 2008 to 2024, it provides a rich collection of studies that aim to enhance understanding and improve practices in the field. As a reference for researchers, practitioners, and students alike, the journal promotes the sharing of innovations and evidence-based methodologies that advance disability studies. The journal operates under a traditional access model, allowing for a broad readership while maintaining high academic standards. With a Scopus rank of #78 out of 665 in its category, the Disability and Health Journal is essential for anyone seeking to contribute to or stay informed about major developments in disability and health research.

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.